Pemetrexed (Alimta)
The Predictive Value of ERCC1, RRM1, and Thymidylate Synthase in Advanced Malignant Pleural Mesothelioma Patients Treated with Platinum-Based Chemotherapy
Asian Pacific Journal of Cancer Prevention 2023 January 1 [Link] Nagwa Ismail Wahba, Ola Khorshid, Fatma Abo Elkasem, Abeer Bahnassy, Rabab Gaafer Abstract Background: A rare yet severe neoplasia called malignant pleural mesothelioma (MPM) typically manifests itself in advanced stages. Despite some improvements in the treatment of patients with MPM, this malignancy continues to have…
Read MoreMesothelioma-associated fibroblasts enhance proliferation and migration of pleural mesothelioma cells via c-Met/PI3K and WNT signaling but do not protect against cisplatin
Journal of Experimental Clinical Cancer Research 2023 January 23 [Link] Alexander Ries, Daniela Flehberger, Astrid Slany, Christine Pirker, Johanna C Mader, Thomas Mohr, Karin Schelch, Katharina Sinn, Berta Mosleh, Mir Alireza Hoda, Balazs Dome, Helmut Dolznig, Georg Krupitza, Leonhard Müllauer, Christopher Gerner, Walter Berger, Michael Grusch Abstract Background: Pleural mesothelioma (PM) is an aggressive malignancy…
Read MoreTislelizumab combined with anlotinib in the second-line treatment of malignant pleural mesothelioma
Medicine 2022 December 30 [Link] Dandan Zhang, Jianping Liang, Yanhua Lv, Xikun Huang, Weihong Guo Abstract Rationale: Malignant pleural mesothelioma (MPM) is a malevolent tumor originated from pleura and often leads to poor prognosis. Chemotherapy of pemetrexed and cisplatin combined with antiangiogenic therapy of bevacizumab is recommended as the first-line regimen by guidelines. However, there…
Read MoreCDK4/6 Inhibition Enhances the Efficacy of Standard Chemotherapy Treatment in Malignant Pleural Mesothelioma Cells
Cancers 2022 November 30 [Link] Rita Terenziani, Maricla Galetti, Silvia La Monica, Claudia Fumarola, Silvia Zoppi, Roberta Alfieri, Graziana Digiacomo, Andrea Cavazzoni, Delia Cavallo, Massimo Corradi, Marcello Tiseo, Pier Giorgio Petronini, Mara Bonelli Abstract Background: The loss of the CDKN2A/ARF (cyclin-dependent kinase inhibitor 2A/alternative reading frame) gene is the most common alteration in malignant pleural…
Read MoreFinal results of DIADEM, a phase II study to investigate the efficacy and safety of durvalumab in advanced pretreated malignant pleural mesothelioma
ESMO Open 2022 December [Link] S Canova, G L Ceresoli, F Grosso, P A Zucali, F Gelsomino, G Pasello, M Mencoboni, E Rulli, F Galli, I De Simone, L Carlucci, A De Angelis, M Belletti, M Bonomi, A D’Aveni, M Perrino, F Bono, D L Cortinovis Abstract Background: Malignant pleural mesothelioma (MPM) is a cancer…
Read MoreDisturbance of the Warburg effect by dichloroacetate and niclosamide suppresses the growth of different sub-types of malignant pleural mesothelioma in vitro and in vivo
Frontiers in Pharmacology 2022 October 11 [Link] Sze-Kwan Lam, Sheng Yan, Joyce Sze-Man Lam, Yuqian Feng, Mahjabin Khan, Caoyang Chen, Frankie Chi-Fat Ko, James Chung-Man Ho Abstract Background: Inhalation of asbestos fibers is the most common cause of malignant pleural mesothelioma (MPM). In 2004, the United States Food and Drug Administration approved a combination of…
Read MoreFinal results of DIADEM, a phase II study to investigate the efficacy and safety of durvalumab in advanced pretreated malignant pleural mesothelioma
ESMO Open 2022 December 1 [Link] S Canova, G L Ceresoli, F Grosso, P A Zucali, F Gelsomino, G Pasello, M Mencoboni, E Rulli, F Galli, I De Simone, L Carlucci, A De Angelis, M Belletti, M Bonomi, A D’Aveni, M Perrino, F Bono, D L Cortinovis, DIADEM groupD Abstract Background: Malignant pleural mesothelioma (MPM)…
Read MoreCHEMORESISTANCE RELATED TO HYPOXIA ADAPTATION IN MESOTHELIOMA CELLS FROM TUMOR SPHEROIDS
Experimental Oncology 2022 August [Link] D Endoh, K Ishii, K Kohno, N Virgona, Y Miyakoshi, T Yano, T Ishida Abstract Background: Hypoxia has been noted as a key factor for induction and maintenance of cancer stemness thereby leading to therapy resistance. Three-dimensional (3D) spheroid models demonstrate a heterogeneity of hypoxic regions replicating the in vivo…
Read MoreMolecular Alterations in Malignant Pleural Mesothelioma: A Hope for Effective Treatment by Targeting YAP
Targeted Oncology 2022 July [Link] Fatéméh Dubois, Céline Bazille, Jérôme Levallet, Elodie Maille, Solenn Brosseau, Jeannick Madelaine, Emmanuel Bergot, Gérard Zalcman, Guénaëlle Levallet Abstract Malignant pleural mesothelioma is a rare and aggressive neoplasm, which has primarily been attributed to the exposure to asbestos fibers (83% of cases); yet, despite a ban of using asbestos in…
Read MoreMolecular Alterations in Malignant Pleural Mesothelioma: A Hope for Effective Treatment by Targeting YAP
Targeted Oncology 2022 July 30 [Link] Fatéméh Dubois, Céline Bazille, Jérôme Levallet, Elodie Maille, Solenn Brosseau, Jeannick Madelaine, Emmanuel Bergot, Gérard Zalcman, Guénaëlle Levallet Abstract Malignant pleural mesothelioma is a rare and aggressive neoplasm, which has primarily been attributed to the exposure to asbestos fibers (83% of cases); yet, despite a ban of using asbestos…
Read More